Zoetis Presents First Excellence In Dermatology Research Grants
Two awards presented to support research in otitis and atopic dermatitis
MADISON, N.J., April 18, 2013 – Zoetis Inc., formerly the animal health business unit of Pfizer Inc., today announced the first recipients of the company’s Excellence in Dermatology™ Research Grant program. The objective of the new program is to support research in the area of basic science diagnosing and treating dermatologic conditions in dogs and cats.
Investigators from the University of Pennsylvania School of Veterinary Medicine and Johns Hopkins University will receive one grant to pursue collaborative research in Pseudomonas otitis in dogs. A second grant is being awarded to a team at the University of Minnesota to study the potential for a new drug target in atopic dermatitis.
“Zoetis is committed to the advancement of clinical science and the improvement of care in the field of companion animal dermatology,” said J. Michael McFarland, DVM, DABVP and group director of Companion Animal Veterinary Operations for Zoetis. “We are pleased to support these research initiatives to advance the scientific understanding of skin disease in dogs and cats and help veterinarians better meet the needs of their patients.”
About the Proposals
One grant is awarded to co-investigators Daniel O. Morris, BS, DVM, MPH, DACVD, and Shelley C. Rankin, BSc (Hons), PhD, of the University of Pennsylvania School of Veterinary Medicine; and Meghan Davis, DVM, PhD, of the Johns Hopkins University Bloomberg School of Public Health to conduct an epidemiologic evaluation of Pseudomonas otitis in dogs.
“Pseudomonas aeruginosa is commonly implicated in severe/chronic cases of otitis externa and otitis media in dogs, and the extensive antimicrobial resistance patterns of most isolates create major therapeutic challenges,” Morris said. “We propose an investigation of the epidemiology of Pseudomonas otitis, and the data generated will be used to address two primary hypotheses: first, that the source of P. aeruginosa in canine otitis is the environment (most likely water and other fluids); and second, that the human companions of these dogs are the vehicles through which transmission/inoculation occurs.”
The other grant goes to Sheila Torres, BS, DVM, MS, PhD, DACVD, and Lucy Vulchanova, BS, PhD, of the University of Minnesota College of Veterinary Medicine, for their proposal titled, “A new drug target for improved epidermal barrier function in atopic dermatitis.”
“Increased susceptibility to infections is a hallmark of atopic dermatitis (AD), a chronic inflammatory skin disorder that affects approximately 10 to 20 percent of dogs,” Torres said. “This increased susceptibility is due in part to impaired epidermal barrier function, which leads to enhanced access of pathogenic bacteria to deeper epidermal layers.
“The objective of our project is to evaluate the relevance of the transient receptor potential channel (TRP) TRPV1 as drug target for treatment of canine AD,” Torres added.
The grant recipients were announced today during a session at the North American Veterinary Dermatology Forum (NAVDF) in Louisville, Ky.
About Excellence in Dermatology
Excellence in Dermatology is a comprehensive resource of clinical information and education materials for veterinarians. The website is part of a commitment by Zoetis to deliver clinically relevant, evidence-based knowledge; insights from leading dermatology experts; and easily
accessible, self-paced materials to veterinarians. Veterinarians can learn more about the program at https://online.zoetis.com/US/EN/Conditions/Pages/Dermatology/index.aspx.
The Excellence in Dermatology Grant program is an example of the Zoetis Commitment to Veterinarians™, a company-wide program to support veterinary students and veterinarians throughout their careers. In an effort to offset the significant costs associated with a veterinary education, Zoetis and the American Veterinary Medical Foundation (AVMF) recently awarded scholarships to 288 second- and third-year veterinary students at accredited universities throughout the United States and the Caribbean. Additionally, Zoetis has recently launched a shared residency program, providing support to a 3-year resident in Dermatology at Tufts University.
More information about the Zoetis Commitment to Veterinarians program is available at https://online.zoetis.com/US/EN/Pages/CommitmentToVeterinarians_US.aspx, on Facebook and on LinkedIn.
Zoetis (zō-EH-tis) is the leading animal health company, dedicated to supporting customers and businesses focused on raising and caring for livestock and companion animals. Building on a 60-year history as the animal health business of Pfizer, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. The company generated annual revenues of $4.3 billion in 2012. It has more than 9,300 employees worldwide and a local presence in approximately 70 countries, including 29 manufacturing facilities in 11 countries. Its products serve veterinarians, livestock producers and people who raise and care for livestock and companion animals in 120 countries. For more information, visit www.zoetis.com.
For further information, Contact:
- Belgium (French)
- Belgium (Dutch)
- Costa Rica
- Czech Republic
- New Zealand
- South Africa
- South Korea
- United Kingdom
- United States